STOCKWATCH: Vertex's almost incomplete disclosure
This article was originally published in Scrip
Executive Summary
That infamous letter from three members of the US House of Representatives to the CEO of Gilead Sciences (which we hold), questioning the price of Sovaldi (sofosbuvir) in the treatment of hepatitis C virus (HCV) infection, has come to be known as the catalyst that started the great biotech sell-off of 2014 (scripintelligence.com, 25 March 2014). The tempo of the debate on US drug pricing was further accelerated when the CEO of the largest pharmacy benefit manager, Express Scripts, warned that the price of Sovaldi was unsustainable and called for its clients to stop using it when competitor drugs gain approval.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.